Two anti-CD19 CAR T-cell products, Tisagenlecleucel (Kymriah) and Axicabtagene Ciloleucel (Yescarta), have been approved by US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.